Key result
Affinity purification coupled with mass spectrometry identified 112 and 350 protein partners of NCX1, with 10 novel partners validated for binding and two increasing NCX1 activity in vitro.
Mapping the cardiac NCX1 interactome identified novel protein partners, such as DYRK1A and SNTB1, which increase NCX1 activity and may represent novel therapeutic targets for heart failure.
The sodium (Na + )‐calcium (Ca 2+ ) exchanger 1 (NCX1) is an antiporter membrane protein encoded by the SLC8A1 gene. In the heart, it maintains cytosolic Ca 2+ homeostasis, serving as the primary mechanism for Ca 2+ extrusion during relaxation. Dysregulation of NCX1 is observed in end‐stage human heart failure. In this study, we used affinity purification coupled with MS in rat left ventricle lysates to identify novel NCX1 interacting proteins in the heart. Two screens were conducted using: (1) anti‐NCX1 against endogenous NCX1 and (2) anti‐His (where His is histidine) with His‐trigger factor‐NCX1 cyt recombinant protein as bait. The respective methods identified 112 and 350 protein partners, of which several were known NCX1 partners from the literature, and 29 occurred in both screens. Ten novel protein partners (DYRK1A, PPP2R2A, SNTB1, DMD, RABGGTA, DNAJB4, BAG3, PDE3A, POPDC2, STK39) were validated for binding to NCX1, and two partners (DYRK1A, SNTB1) increased NCX1 activity when expressed in HEK293 cells. A cardiac NCX1 protein–protein interaction map was constructed. The map was highly connected, containing distinct clusters of proteins with different biological functions, where “cell communication” and “signal transduction” formed the largest clusters. The NCX1 interactome was also significantly enriched with proteins/genes involved in “cardiovascular disease” which can be explored as novel drug targets in future research.
No takes yet. Share an insight, caveat, or question.
Hafver et al. (2017) studied Heart failure / NCX1 dysregulation. Affinity purification coupled with MS was evaluated on Identification of NCX1 interacting proteins. Affinity purification coupled with mass spectrometry identified 112 and 350 protein partners of NCX1, with 10 novel partners validated for binding and two increasing NCX1 activity in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: